Explore the critical insights into the healthcare challenges faced by multiple myeloma patients undergoing innovative T cell redirection therapies.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Unscheduled healthcare interactions in multiple myeloma patients receiving T cell redirection therapies.
Howard et al., Blood Adv 2024
<!– DOI: 10.1182/bloodadvances.2024012871 //–>
https://doi.org/10.1182/bloodadvances.2024012871
A study focusing on relapsed/refractory multiple myeloma (RRMM) patients treated with B cell maturation antigen targeted therapies, including bispecific antibody (BsAb) and chimeric antigen receptor (CAR) T cell therapies, revealed significant insights into healthcare utilization. Analyzing a cohort of 46 RRMM patients, the research found that 89% of these patients had unscheduled healthcare interactions (UHIs) within the first 125 days of treatment, averaging 3.7 UHIs per patient. Notably, patients receiving BsAb therapy were more likely to engage in remote communications with their healthcare providers or visit urgent care centers compared to those on CAR T cell therapy, primarily due to mild upper respiratory tract infections. This highlights a critical need for preemptive symptom management strategies to potentially reduce unnecessary healthcare utilization among RRMM patients undergoing these advanced treatments.